Nanollose (ASX:NC6) - Stock price, News & Analysis

NC6 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

NC6 Stock Overview

Nanollose Limited, a biotechnology company, engages in the research and development, and promotion of the microbial nanocellulose technology in Australia.

Risk Analysis

Earnings have declined by 5.8% per year over past 5 years

Makes less than USD$1m in revenue (A$323K)

Does not have a meaningful market cap (A$13M)

Volatile share price over the past 3 months

+ 1 more risk

Price History & Performance

Summary of all time highs, changes and price drops for Nanollose
Historical stock prices
Current Share Price	AU$0.09
52 Week High	AU$0.18
52 Week Low	AU$0.08
Beta	-0.043
1 Month Change	-10.00%
3 Month Change	-7.22%
1 Year Change	-48.57%
3 Year Change	-9.09%
5 Year Change	n/a
Change since IPO	-63.27%

Shareholder Returns

	NC6	AU Biotechs	AU Market
7D	-5.3%	-5.3%	-5.4%
1Y	-48.6%	-6.1%	2.6%

Return vs Industry: NC6 underperformed the Australian Biotechs industry which returned -6.1% over the past year.

Return vs Market: NC6 underperformed the Australian Market which returned 2.6% over the past year.

Price Volatility

Is NC6's price volatile compared to industry and market?
NC6 volatility
NC6 Average Weekly Movement	12.7%
Biotechs Industry Average Movement	9.4%
Market Average Movement	8.5%
10% most volatile stocks in AU Market	15.4%
10% least volatile stocks in AU Market	3.7%

Stable Share Price: NC6 is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: NC6's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

Founded	Employees	CEO	Website
2014	n/a	n/a	https://www.nanollose.com

Nanollose Limited, a biotechnology company, engages in the research and development, and promotion of the microbial nanocellulose technology in Australia. It offers Nullarbor Fibre, a plant-free viscose-rayon fibre; Nullarbor Garment, a wearable garment using Nullarbor tree-free rayon; and Jelli Grow, an alternative seed germination and plant growing material. The company’s products are used in textiles, nonwoven fabric, and other industries.

Nanollose Fundamentals Summary

How do Nanollose's earnings and revenue compare to its market cap?
NC6 fundamental statistics
Market Cap	AU$13.40m
Earnings (TTM)	-AU$931.04k
Revenue (TTM)	AU$322.86k

41.7x

P/S Ratio

-14.4x

P/E Ratio

Is NC6 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
NC6 income statement (TTM)
Revenue	AU$322.86k
Cost of Revenue	AU$393.43k
Gross Profit	-AU$70.57k
Expenses	AU$860.47k
Earnings	-AU$931.04k

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0063
Gross Margin	-21.86%
Net Profit Margin	-288.38%
Debt/Equity Ratio	0.9%

How did NC6 perform over the long term?

See historical performance and comparison

Valuation

Is Nanollose undervalued compared to its fair value and its price relative to the market?

4.66x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NC6's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate NC6's fair value to establish if it is undervalued.

Price To Earnings Ratio

PE vs Industry: NC6 is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.

PE vs Market: NC6 is unprofitable, so we can't compare its PE Ratio to the Australian market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NC6's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: NC6 is overvalued based on its PB Ratio (4.7x) compared to the AU Biotechs industry average (3.8x).

Future Growth

How is Nanollose forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

10.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nanollose has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Nanollose performed over the past 5 years?

-5.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: NC6 is currently unprofitable.

Growing Profit Margin: NC6 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: NC6 is unprofitable, and losses have increased over the past 5 years at a rate of 5.8% per year.

Accelerating Growth: Unable to compare NC6's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NC6 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (48.2%).

Return on Equity

High ROE: NC6 has a negative Return on Equity (-32.4%), as it is currently unprofitable.

Financial Health

How is Nanollose's financial position?

Financial Position Analysis

Short Term Liabilities: NC6's short term assets (A$3.1M) exceed its short term liabilities (A$507.8K).

Long Term Liabilities: NC6 has no long term liabilities.

Debt to Equity History and Analysis

Debt Level: NC6 has more cash than its total debt.

Reducing Debt: NC6 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NC6 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: NC6 has sufficient cash runway for 3 years if free cash flow continues to reduce at historical rates of 13.3% each year.

Dividend

What is Nanollose current dividend yield, its reliability and sustainability?

Dividend Yield vs Market

Notable Dividend: Unable to evaluate NC6's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NC6's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NC6's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NC6's dividend payments have been increasing.

Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NC6's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

CEO

Nanollose has no CEO, or we have no data on them.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25%.

Data	Last Updated (UTC time)
Company Analysis	2022/01/26 07:02
End of Day Share Price	2022/01/25 00:00
Earnings	2021/06/30
Annual Earnings	2021/06/30